Symbyax Related Published Studies
Well-designed clinical trials related to Symbyax (Olanzapine / Fluoxetine)
Pharmacokinetic evaluation of olanzapine + fluoxetine for the treatment of
bipolar depression. [2013]
Association of common variations in the norepinephrine transporter gene with
response to olanzapine-fluoxetine combination versus continued-fluoxetine
treatment in patients with treatment-resistant depression: a candidate gene
analysis. [2012]
Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. [2010.05]
Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients. [2010.01.30]
Olanzapine/fluoxetine combination in patients with treatment-resistant
depression: rapid onset of therapeutic response and its predictive value for
subsequent overall response in a pooled analysis of 5 studies. [2010]
Genetic associations of prolactin increase in olanzapine/fluoxetine
combination-treated patients. [2010]
Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. [2009.08]
Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. [2009.07]
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. [2007.02]
A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. [2006.07]
Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction. [2005.07]
Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. [2005.05]
Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data. [2004.10]
A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. [2004.08]
A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. [2004.07]
Olanzapine in bipolar disorder. [2004.07]
A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. [2004.03.01]
Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. [2004.01]
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. [2003.11]
Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. [2003.03]
Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. [2002.10]
Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. [2002.06]
Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial. [2002.05]
Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial. [2002.05]
Well-designed clinical trials possibly related to Symbyax (Olanzapine / Fluoxetine)
Treatment options for bipolar depression: a systematic review of randomized, controlled trials. [2010.10]
Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. [2010.02]
Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. [2009.12]
Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. [2009.07.29]
An update on the treatment of bipolar depression. [2009.02]
Newer treatment studies for bipolar depression. [2005]
Bipolar depression: a new role for atypical antipsychotics? [2005]
A novel augmentation strategy for treating resistant major depression. [2001.01]
Other research related to Symbyax (Olanzapine / Fluoxetine)
Olanzapine plus fluoxetine for bipolar disorder: a systematic review and
meta-analysis. [2013]
Olanzapine?fluoxetine combination for the treatment of bipolar depression. [2011.12]
Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination: an analysis of 2 adult studies in treatment-resistant depression. [2011.06]
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women. [2011.05.15]
Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. [2010.07]
Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression. [2010.05]
Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. [2010.04]
Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder. [2010.03.01]
Efficacy, safety and tolerability of Symbyax for acute-phase management of
treatment-resistant depression. [2010]
Genetic association study of treatment response with olanzapine/fluoxetine
combination or lamotrigine in bipolar I depression. [2010]
Effects of olanzapine, fluoxetine and olanzapine/fluoxetine on creatine kinase activity in rat brain. [2009.12.16]
Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. [2009.10]
An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. [2009.03]
Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. [2008.12.11]
Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility. [2008.09]
Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression. [2008]
Spotlight on olanzapine/fluoxetine in acute bipolar depression. [2008]
Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. [2007.09]
Olanzapine/fluoxetine combination for bipolar depression and other mood disorders: a review. [2006.03]
Olanzapine/fluoxetine combination for bipolar depression. [2006.01]
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. [2006]
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. [2005.11]
Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. [2005.10]
Olanzapine Augmentation of Fluoxetine for Refractory Generalized Anxiety Disorder: A Placebo Controlled Study. [2005.08.31]
Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder. [2005.08]
Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. [2004.10.15]
Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity. [2004.06.01]
Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. [2004.06.01]
Serotonin syndrome associated with fluoxetine and olanzapine. [2004.04]
Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. [2004.02]
Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. [2003.11]
Olanzapine treatment of an adolescent girl with anorexia nervosa. [2003.07]
The combination of olanzapine and fluoxetine in mood disorders. [2003.07]
Economic impact of olanzapine plus fluoxetine combination therapy among patients treated for depression: a pilot study. [2003.06]
Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. [2003.02]
An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. [2002.12]
Influence of fluoxetine on olanzapine pharmacokinetics. [2002]
Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. [2001.04]
Melancholic symptoms during concurrent olanzapine and fluoxetine. [2000.09]
Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. [2000.07]
Olanzapine. Pharmacokinetic and pharmacodynamic profile. [1999.09]
Other possibly related research studies
Bipolar depression: the role of atypical antipsychotics. [2004.11]
Antidepressant-induced adverse reactions in a patient with hemorrhagic stroke. [2005.10]
Clinical highlights in bipolar depression: focus on atypical antipsychotics. [2005]
Latest therapies for bipolar disorder. Looking beyond lithium. [2005.02]
[Efficacy of atypical antipsychotics in depressive syndromes.] [2004.11]
Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. [2005]
Gateways to clinical trials. [2004.11]
Cortical 3 alpha-hydroxy-5 alpha-pregnan-20-one levels after acute administration of Delta 9-tetrahydrocannabinol, cocaine and morphine. [2005.05]
Gateways to clinical trials. [2004.10]
Pharmacotherapy of pervasive developmental disorders in children and adolescents. [2004]
Available pharmacological treatments for anorexia nervosa. [2004.11]
New medication treatment options for bipolar disorders. [2004]
Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? [2004]
Using antipsychotic agents in older patients. [2004]
The role of atypical antipsychotics in bipolar depression and anxiety disorders. [2003]
Towards the pharmacotherapy of eating disorders. [2003.10]
Drug therapy for patients with eating disorders. [2003.02]
New approaches to managing psychotic depression. [2003]
Gateways to Clinical Trials. June 2002. [2002.06]
Body weight changes associated with psychopharmacology. [2002.07]
Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. [2002]
What role do atypical antipsychotic drugs have in treatment-resistant depression? [2002.02]
Studies on modulation of feeding behavior by atypical antipsychotics in female mice. [2002.02]
Clozapine enhances breakpoint in common marmosets responding on a progressive ratio schedule. [2001.05]
Antibodies against human putamen in adolescents with anorexia nervosa. [2001.05]
Treatment of bipolar depression with twice-weekly fluoxetine: management of antidepressant-induced mania. [2001.01]
Differences in interactions of SSRIs. [1998.09]
Quetiapine: a new atypical antipsychotic. [1998.06]
|